Neuropacs™ Corp.

Neuropacs™ Corp. , based in the US, specializes in advanced digital solutions for neurological diagnostics, providing tools that enhance the performance and efficiency of neurology practices. Neuropacs™ Corp. was founded in 2023 in Gainesville, US, focusing on innovative solutions for neurological diagnostics.

The company has completed one deal, with its most recent funding round being a SEED round in January 2026, raising USD 1. 000 mn from Neuro Investment Group, LLC. The total amount raised by the company also stands at USD 1. 000 mn.

Neuropacs. com specializes in providing advanced digital solutions aimed at enhancing the performance and efficiency of neurological diagnostics. Their core offerings include a suite of software and hardware tools designed for neurology practices, allowing for more accurate patient evaluations and improved workflow management. The products are utilized primarily in clinical settings, targeting neurologists, hospitals, and specialized clinics that require precise diagnostics for conditions such as epilepsy, migraines, and other neurological disorders.

Neuropacs serves a diverse client base across North America and Europe, focusing on markets where there is a significant demand for innovative healthcare technologies. The solutions are tailored to meet the specific needs of healthcare professionals, facilitating timely and reliable patient care while ensuring compliance with industry standards. The revenue model for Neuropacs revolves around a combination of subscription-based services and direct sales of their diagnostic tools. Clients typically engage in annual subscription agreements that provide access to software updates, technical support, and continuous education resources.

Transactions are structured to support both B2B and direct-to-consumer sales, allowing healthcare facilities to integrate Neuropacs products into their existing systems seamlessly. Flagship offerings play a crucial role in revenue generation, with clients acquiring these products to enhance their diagnostic capabilities. Specific pricing plans are determined based on the scale of deployment and the specific needs of client institutions, ensuring flexibility and accessibility for a wide range of healthcare providers. This structured approach facilitates steady revenue streams while fostering long-term partnerships with clients in the healthcare sector.

In January 2026, Neuropacs™ Corp. raised USD 1. 000 mn in seed funding, which will be utilized to accelerate technology development, key recruiting, and strategic partnerships. The company has plans to expand into new markets, focusing on both North America and Europe with targeted outreach efforts scheduled for mid-2026.

Neuropacs is also developing new products aimed at enhancing their diagnostic capabilities, with additional product launches expected in late 2026.